Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 March 2023 - 11:58PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2023
Commission File Number: 001-39137
AnPac
Bio-Medical Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
On
March 23, 2023, the Registrant issued a press release reporting that a NASDAQ Hearing Panel has granted the Registrant continued listing
on the NASDAQ Capital Market subject to the requirement that the Registrant demonstrate on or before July 12, 2023, its compliance
with the NASDAQ shareholder equity requirement, as outlined in Listing Rule 5550(b)(1).
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
AnPac Bio-Medical Science Co., Ltd. |
|
|
|
By: |
/s/Haohan Xu |
|
Name: |
Haohan Xu |
|
Title: |
Co-Chief Executive Officer |
|
|
|
Dated: March 23, 2023 |
|
|
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to Apr 2024